Pelthos Therapeutics Inc. PTHS 深 沪
已收盘 03-27 16:00:00 美东时间
22.49
-0.250
-1.10%
华盛通- 最 高26.00
- 今 开23.38
- 成交量 4674股
- 最 低 22.49
- 昨 收 22.74
- 总市值 7546.52万
- 52周最高 54.29
- 市盈率 静 --
- 换手率 0.14%
- 52周最低 9.00
- 委 比 13.64%
- 总股本 335.55万
- 历史最高 60.00
- 量 比 1.02
- 振 幅 15.44%
- 历史最低 4.50
- 每 手 1
- 风险率 7.27%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 小摩、瑞穗等下调阿里目标价最低至164美元；达登饭店、联邦快递、林肯教育服务、Planet Labs等获多家大行上调目标价
今日重点评级关注：瑞穗：维持RELMADA THERAPEUTICS"跑赢大市"评级，目标价从10美元升至19美元；奥本海默：维持Pelthos Therapeutics"跑赢大市"评级，目标价从60美元升至62美元
03-23 13:53
美股大行评级 | 最高700美元！大摩、瑞银等10家大行集体上调美光目标价；通用磨坊、梅西百货、SailPoint等遭多家大行下调目标价
今日重点评级关注：RBC Capital：维持4D Molecular Therapeutics"跑赢大市"评级，目标价从32美元升至35美元；巴克莱：维持CytomX医疗"超配"评级，目标价从10美元升至16美元
03-20 15:53
Earnings Scheduled For March 19, 2026
Companies Reporting Before The Bell • Neuraxis (AMEX:NRXS) is projected to repo...
03-19 19:11
Pelthos Therapeutics Q4 EPS $(6.87) Misses $(4.13) Estimate, Sales $9.389M Beat $9.090M Estimate
Pelthos Therapeutics (AMEX:PTHS) reported quarterly losses of $(6.87) per share which missed the analyst consensus estimate of $(4.13) by 66.34 percent. This is a 115.36 percent decrease over losses of $(3.19) per share
03-19 18:33
Pelthos Q4 net loss widens to USD 21.66 million as ZELSUVMI net product revenue rises 28% to USD 9.09 million
Pelthos Q4 net loss widens to USD 21.66 million as ZELSUVMI net product revenue rises 28% to USD 9.09 million Pelthos published a press release reporting Q4 and FY 2025 financial results. Q4 net product revenues were USD 9.09 million, up 28% quarter over quarter. Q4 operating loss narrowed to USD 12
03-19 18:30
Pelthos Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026
Pelthos Therapeutics will report Q4 and full-year 2025 financial results on March 19, 2026, followed by a conference call at 8:00 a.m. ET. Details include dial-in numbers (1-877-451-6152 for U.S., 1-201-389-0879 for international) and passcode 13758894. A webcast will also be available at [link]. The company focuses on therapeutic products for skin infections, including ZELSUVMI™, Xepi®, and Xeglyze®.
03-09 12:30
美股大行评级 | 下调居多！多邻国、Elastic、Flutter、欧特克、Zscaler等遭多家机构下调目标价
今日重点评级关注：巴克莱：维持C4 Therapeutics"超配"评级，目标价从5美元升至7美元；富国银行：维持Agilon Health"超配"评级，目标价从1美元升至1.5美元
03-02 14:08
美股大行评级 | 最高300美元！大摩、小摩、花旗纷纷上调英伟达目标价；赛富时、C3.ai、Snowflake、Trade Desk等遭数十家机构下调目标价
今日重点评级关注：HC Wainwright & Co.：维持NovoCure"买入"评级，目标价从47美元升至49美元；Citizens：维持Ironwood医药"跑赢大市"评级，目标价从8美元升至10美元
02-27 11:07
Pelthos Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Pelthos Therapeutics Inc. (NYSE American: PTHS) announced that its CEO, Scott Plesha, will present at the Oppenheimer 36th Annual Healthcare Life Sciences conference on February 26, 2026, at 10:00 a.m. Eastern Time. The presentation will be available via webcast at [link] and under “News & Events” on the company’s website, with a replay available for 90 days. Pelthos, a biopharmaceutical company focused on cutaneous infectious disease products, i...
02-23 13:00
美股大行评级 | 斯伦贝谢、SouthState Bank、西屋制动、特里科银行获多家大行上调目标价；苹果、meta、微软等绩前遭下调目标价
今日重点评级关注：Oppenheimer：维持Pelthos Therapeutics"跑赢大市"评级，目标价从57美元升至60美元；Small Cap Consumer Research：维持Lands' End"买入"评级，目标价从20美元升至45美元
01-27 10:02
